Demonstrating efficacy is critical for regulatory approval of new vaccine candidates. Identifying immune biomarkers can help accelerate vaccine development by serving as a reliable indicator of protection with simple laboratory tests, eliminating the need for lengthy clinical trials. This fact sheet summarizes PATH’s work on exploring how artificial intelligence (AI) could be leveraged to speed the identification of potential immune biomarkers that may correlate with protection from disease, with the goal of bringing new vaccines to market sooner.